Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.06
NYSE:DHR's Cash-to-Debt is ranked lower than
93% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. NYSE:DHR: 0.06 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:DHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.19 Max: N/A
Current: 0.06
Equity-to-Asset 0.54
NYSE:DHR's Equity-to-Asset is ranked lower than
63% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NYSE:DHR: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:DHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.16  Med: 0.51 Max: 0.67
Current: 0.54
0.16
0.67
Interest Coverage 17.42
NYSE:DHR's Interest Coverage is ranked lower than
61% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.16 vs. NYSE:DHR: 17.42 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:DHR' s Interest Coverage Range Over the Past 10 Years
Min: 12.58  Med: 16.69 Max: 22.1
Current: 17.42
12.58
22.1
Piotroski F-Score: 6
Altman Z-Score: 2.93
Beneish M-Score: -2.66
WACC vs ROIC
7.16%
7.25%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 15.69
NYSE:DHR's Operating Margin % is ranked higher than
83% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. NYSE:DHR: 15.69 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:DHR' s Operating Margin % Range Over the Past 10 Years
Min: 13.79  Med: 16.08 Max: 17.33
Current: 15.69
13.79
17.33
Net Margin % 12.63
NYSE:DHR's Net Margin % is ranked higher than
85% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.21 vs. NYSE:DHR: 12.63 )
Ranked among companies with meaningful Net Margin % only.
NYSE:DHR' s Net Margin % Range Over the Past 10 Years
Min: 10.3  Med: 13.9 Max: 23.26
Current: 12.63
10.3
23.26
ROE % 9.20
NYSE:DHR's ROE % is ranked higher than
65% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.23 vs. NYSE:DHR: 9.20 )
Ranked among companies with meaningful ROE % only.
NYSE:DHR' s ROE % Range Over the Past 10 Years
Min: 9.2  Med: 13.64 Max: 17.42
Current: 9.2
9.2
17.42
ROA % 4.81
NYSE:DHR's ROA % is ranked higher than
69% of the 228 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.45 vs. NYSE:DHR: 4.81 )
Ranked among companies with meaningful ROA % only.
NYSE:DHR' s ROA % Range Over the Past 10 Years
Min: 4.81  Med: 7.75 Max: 9.03
Current: 4.81
4.81
9.03
ROC (Joel Greenblatt) % 63.38
NYSE:DHR's ROC (Joel Greenblatt) % is ranked higher than
87% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. NYSE:DHR: 63.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:DHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 59.73  Med: 82.44 Max: 118.82
Current: 63.38
59.73
118.82
3-Year Revenue Growth Rate -2.10
NYSE:DHR's 3-Year Revenue Growth Rate is ranked lower than
70% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. NYSE:DHR: -2.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:DHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -9.7  Med: 9.7 Max: 47.6
Current: -2.1
-9.7
47.6
3-Year EBITDA Growth Rate -3.30
NYSE:DHR's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NYSE:DHR: -3.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:DHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19  Med: 11.7 Max: 51.5
Current: -3.3
-19
51.5
3-Year EPS without NRI Growth Rate -5.50
NYSE:DHR's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. NYSE:DHR: -5.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:DHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: 14.7 Max: 92
Current: -5.5
-33.7
92
GuruFocus has detected 6 Warning Signs with Danaher Corp $NYSE:DHR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:DHR's 30-Y Financials

Financials (Next Earnings Date: 2017-10-20 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

DHR Guru Trades in Q3 2016

George Soros 7,970 sh (New)
Robert Olstein 47,000 sh (New)
Joel Greenblatt 596,095 sh (New)
Caxton Associates 120,000 sh (New)
Louis Moore Bacon 38,781 sh (+949.27%)
Paul Tudor Jones 65,140 sh (+499.87%)
Ray Dalio 75,600 sh (+245.44%)
Steven Cohen 338,100 sh (+126.36%)
Jim Simons 857,000 sh (+60.49%)
Ruane Cunniff 1,821,908 sh (+17.86%)
Daniel Loeb 4,500,000 sh (+16.88%)
First Eagle Investment 2,450,049 sh (+5.39%)
Ken Fisher 5,760 sh (+1.11%)
Chuck Akre 1,500,000 sh (unchged)
John Hussman 30,000 sh (unchged)
Mairs and Power Sold Out
Manning & Napier Advisors, Inc Sold Out
Pioneer Investments Sold Out
Murray Stahl 36,171 sh (-0.08%)
John Griffin 2,246,000 sh (-3.14%)
Dodge & Cox 5,715,408 sh (-14.11%)
Mario Gabelli 10,751 sh (-50.57%)
Jeremy Grantham 3,826 sh (-60.63%)
John Burbank 40,000 sh (-70.64%)
» More
Q4 2016

DHR Guru Trades in Q4 2016

Paul Tudor Jones 484,432 sh (+643.68%)
Steven Cohen 663,300 sh (+96.18%)
Jim Simons 1,522,100 sh (+77.61%)
First Eagle Investment 3,157,097 sh (+28.86%)
Robert Olstein 55,000 sh (+17.02%)
Chuck Akre 1,655,300 sh (+10.35%)
Mario Gabelli 11,196 sh (+4.14%)
John Hussman 30,000 sh (unchged)
George Soros Sold Out
Caxton Associates Sold Out
Ray Dalio Sold Out
John Burbank Sold Out
Murray Stahl 35,587 sh (-1.61%)
Ruane Cunniff 1,733,275 sh (-4.86%)
Dodge & Cox 5,221,273 sh (-8.65%)
Ken Fisher 5,127 sh (-10.99%)
Jeremy Grantham 3,226 sh (-15.68%)
John Griffin 1,760,000 sh (-21.64%)
Daniel Loeb 3,250,000 sh (-27.78%)
Joel Greenblatt 420,700 sh (-29.42%)
» More
Q1 2017

DHR Guru Trades in Q1 2017

Caxton Associates 7,300 sh (New)
Ray Dalio 16,638 sh (New)
Louis Moore Bacon 125,201 sh (+222.84%)
Robert Olstein 65,000 sh (+18.18%)
Ken Fisher 5,224 sh (+1.89%)
Chuck Akre 1,655,300 sh (unchged)
John Hussman 30,000 sh (unchged)
John Griffin 1,760,000 sh (unchged)
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Dodge & Cox 5,099,223 sh (-2.34%)
Ruane Cunniff 1,664,622 sh (-3.96%)
Murray Stahl 34,135 sh (-4.08%)
Jim Simons 1,459,300 sh (-4.13%)
Mario Gabelli 10,696 sh (-4.47%)
Daniel Loeb 3,100,000 sh (-4.62%)
First Eagle Investment 2,623,552 sh (-16.90%)
Joel Greenblatt 269,309 sh (-35.99%)
» More
Q2 2017

DHR Guru Trades in Q2 2017

Ken Fisher 5,423 sh (+3.81%)
» More
» Details

Insider Trades

Latest Guru Trades with DHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:TMO, NYSE:A, NYSE:Q, NYSE:LH, NYSE:DGX, NAS:IDXX, NYSE:PKI, NYSE:BIO, NAS:DXCM, NYSE:CRL, NAS:PRAH, NAS:BRKR, NAS:EXAS, NAS:PRXL, NYSE:ALR, NAS:VWR, NAS:INCR, NAS:NEOG, NAS:MYGN, NAS:AXDX » details
Traded in other countries:DHER34.Brazil, DAP.Germany, DHR.Mexico, DHR.Switzerland, 0R2B.UK,
Headquarter Location:USA
Danaher Corp designs, manufactures and markets professional, medical, industrial and commercial products and services. It markets its products under the brand of Beckman Coulter, Aperio, Dexis, Chemtreat and others.

After the spin-off of Fortive in 2016, Danaher is a diversified and mostly healthcare-focused instrument and supplies manufacturer. After the spin, Danaher retains four main business segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. Each segment represents approximately 32%, 31%, 16%, and 21% of revenue, respectively.

Guru Investment Theses on Danaher Corp

Daniel Loeb Comments on Danaher - Apr 27, 2016

Danaher (DHR) is a diversified multi-industrial company with an increasing exposure to life science and healthcare-oriented businesses. Operating across five different business segments and built up through over 400 acquisitions over the company’s history, the cornerstone for Danaher’s successful integration and value creation strategy has been the

Danaher Business System (DBS). Adapted from Japanese principles of kaizen, DBS has evolved into a set of processes and corporate culture revolving around continuous improvement, helping to drive organic growth and annual margin improvement across Danaher’s portfolio.

In May 2015, Danaher announced the acquisition of a filtration industry leader, Pall Corp, as well as the subsequent split of Danaher into two companies. The split, to be effectuated Q3 2016, will highlight value at both New Danaher – a collection of Danaher’s life science, medical and lower cyclicality businesses – and the spin-off, Fortive – an industrial focused “mini-Danaher”.

New Danaher, representing the large majority of post-split value, will have 60% consumables sales mix, 4% organic growth, 100bps of annual margin expansion, and>100% FCF conversion, an algorithm that will continue the Danaher tradition of compounded earnings growth. The attractive end-market mix, earnings growth, and deep bench of DBS operators will make New Danaher a premium life sciences company that should trade at the high end of its peer group.

Fortive, akin to what Danaher originally looked like two decades ago, will have greatly increased M&A optionality and the ability to deploy free cash flow into assets which have historically received less focus within the Danaher portfolio. With the same DBS roots and team of disciplined operators, Fortive will also provide a multi-year compounding opportunity.

We initiated a position following the announcements last summer which mark a transformational step in Danaher’s decade-long efforts to continuously improve its portfolio of businesses. Despite Danaher’s portfolio of businesses looking more attractive than ever, its current valuation premium to the S&P 500 is modest and remains well below its ten year historical average premium. Over the last ten years, Danaher has compounded at 2x the rate of the S&P 500. We recently added to the position after a meeting with the company reinforced our confidence not only in their operations but also in the company’s culture and importance of their values and principles in driving future success.

From Daniel Loeb (Trades, Portfolio)'s first quarter 2016 shareholder letter.

Check out Daniel Loeb latest stock trades

Sequoia Fund Coments on Danaher - Aug 28, 2015

Terence Paré:



Danaher (NYSE:DHR) is in a lot of different businesses. It started out as an industrial company making things like hand tools and engine retarders. It used to make Craftsman mechanics tools. But the company right now is basically — and in fact has reclassified its documentation with the SEC — to that for industrial instruments. Danaher makes things like oscilloscopes, mass spectrometers. It has a very significant dental business. But it still sells Matco hand tools, which are sold in vans that drive around to garages, industrial printers, medical gear, water treatment equipment, and more.



The business right now is in the headlines a lot because management recently announced that it is going to break Danaher into three pieces and it is going to acquire Pall, which is an industrial filter company. One piece will be Pall and Danaher’s instruments piece, and another will be the industrial businesses. On top of that, Danaher has a communications business. This is part of an earlier acquisition and was originally called Tektronix Communications. Without getting too far under the hood, Tektronix Communications makes gear and software that keep track of the way that the IT infrastructure works in enterprises. For example, it will track if there is some weird glitch going on somewhere in your enterprise system.



Danaher has decided to combine that piece of its business with a company called NetScout, which further complicates things because shareholders are going to be offered the opportunity to swap their Danaher shares for NetScout shares. These are very different businesses from the rest of the company. When the communications piece was in Danaher, it was fun to talk about, but it was relatively small. When it is combined with NetScout, we are going to have to make a decision about how we want to go about dealing with our Danaher stock. I am still working on this. Most of the big news about Danaher has only occurred in the past week or so. So we are still noodling over it. But like Mohawk, Danaher is one of our oldest positions. I think only Berkshire has been in the portfolio longer. Danaher has been a very good investment for us. Where we go from here right now is hard to say because we can elect to own one, two, or three pieces.



One thing I would say, and this speaks to a principle that Bob has pointed to before, and that is that there is significant insider ownership of Danaher by the Rales brothers. They will continue to serve on the boards of both companies after they split it apart. And Jim Lico, a Danaher executive vice president, will serve on NetScout’s board. What is not clear to me is whether or in which entity or entities the Rales brothers are going to elect to receive a percentage of shares disproportionately higher or lower than their current ownership of Danaher. The Rales have made an awful lot of money for themselves — and they have made, relatively speaking on a percentage basis, a lot of money for us. They are not going to do anything ill-advised.



From Ruane, Cunniff & Goldfarb Investor Day 2015 Transcript Part II - Sequoia Fund.



Check out Ruane Cunniff latest stock trades

Top Ranked Articles about Danaher Corp

Danaher Schedules Second Quarter 2017 Earnings Conference Call
Danaher Announces Pricing Of Euro-Denominated Senior Notes Offering
Danaher to Present at Goldman Sachs Global Healthcare Conference
Danaher To Present At Bernstein Strategic Decisions Conference
Danaher To Present At Bank Of America Merrill Lynch Health Care Conference
Danaher Announces Quarterly Dividend
Danaher Reports First Quarter 2017 Results
Valeant: It's Not a Game of Chess - The Lessons Six lessons from the Valeant case study
In my previous four articles on Valeant (Part I, II, III and IV), I went through my findings regarding Valeant’s (NYSE:VRX) business model and what went wrong. We all know that Valeant’s shares have plummeted more than 90% since the peak they reached in the first half of 2015. There’s some ongoing debate as to whether there’s any value in Valeant’s stock at today’s price. I’m not going to attempt to value Valeant because I’m not even interested at this point. On the other hand, there are quite a few lessons we can learn from the debacle of Valeant and why so many high-grade people it took in. Read more...
A Socially Conscious Guru Jerome Dodson wants companies, but they also must be 'good' companies, concerned about the environment, society beyond just shareholders and corporate governance
Chuck Akre Buys Moody's and Dollar General, Sells MasterCard The guru's largest 4th-quarter trades
Chuck Akre (Trades, Portfolio) is the founder of Akre Capital Management LLC. During the fourth quarter the guru traded shares in the following stocks: Read more...

Ratios

vs
industry
vs
history
PE Ratio 26.60
DHR's PE Ratio is ranked higher than
69% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.78 vs. DHR: 26.60 )
Ranked among companies with meaningful PE Ratio only.
DHR' s PE Ratio Range Over the Past 10 Years
Min: 9.61  Med: 14.69 Max: 27.74
Current: 26.6
9.61
27.74
Forward PE Ratio 21.10
DHR's Forward PE Ratio is ranked higher than
71% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.92 vs. DHR: 21.10 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 26.69
DHR's PE Ratio without NRI is ranked higher than
70% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 38.46 vs. DHR: 26.69 )
Ranked among companies with meaningful PE Ratio without NRI only.
DHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.58  Med: 15.53 Max: 38.03
Current: 26.69
9.58
38.03
Price-to-Owner-Earnings 25.73
DHR's Price-to-Owner-Earnings is ranked higher than
66% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.54 vs. DHR: 25.73 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.59  Med: 11.63 Max: 26.84
Current: 25.73
7.59
26.84
PB Ratio 2.34
DHR's PB Ratio is ranked higher than
71% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. DHR: 2.34 )
Ranked among companies with meaningful PB Ratio only.
DHR' s PB Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.86 Max: 2.82
Current: 2.34
1.19
2.82
PS Ratio 3.34
DHR's PS Ratio is ranked higher than
59% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.65 vs. DHR: 3.34 )
Ranked among companies with meaningful PS Ratio only.
DHR' s PS Ratio Range Over the Past 10 Years
Min: 1.01  Med: 1.87 Max: 4.35
Current: 3.34
1.01
4.35
Price-to-Free-Cash-Flow 24.24
DHR's Price-to-Free-Cash-Flow is ranked higher than
58% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. DHR: 24.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.59  Med: 12.85 Max: 25.3
Current: 24.24
7.59
25.3
Price-to-Operating-Cash-Flow 19.28
DHR's Price-to-Operating-Cash-Flow is ranked higher than
58% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.14 vs. DHR: 19.28 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.81  Med: 11.49 Max: 20.11
Current: 19.28
6.81
20.11
EV-to-EBIT 26.80
DHR's EV-to-EBIT is ranked higher than
57% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DHR: 26.80 )
Ranked among companies with meaningful EV-to-EBIT only.
DHR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 12.5 Max: 35.6
Current: 26.8
8
35.6
EV-to-EBITDA 18.28
DHR's EV-to-EBITDA is ranked higher than
60% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.58 vs. DHR: 18.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
DHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 10.3 Max: 26.1
Current: 18.28
6.7
26.1
Shiller PE Ratio 24.85
DHR's Shiller PE Ratio is ranked higher than
81% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.44 vs. DHR: 24.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
DHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.2  Med: 22.74 Max: 35.29
Current: 24.85
15.2
35.29
Current Ratio 1.49
DHR's Current Ratio is ranked lower than
87% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. DHR: 1.49 )
Ranked among companies with meaningful Current Ratio only.
DHR' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.42 Max: 2.23
Current: 1.49
0.9
2.23
Quick Ratio 1.06
DHR's Quick Ratio is ranked lower than
89% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. DHR: 1.06 )
Ranked among companies with meaningful Quick Ratio only.
DHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 0.98 Max: 1.82
Current: 1.06
0.56
1.82
Days Inventory 85.95
DHR's Days Inventory is ranked lower than
52% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.72 vs. DHR: 85.95 )
Ranked among companies with meaningful Days Inventory only.
DHR' s Days Inventory Range Over the Past 10 Years
Min: 63.09  Med: 71.38 Max: 108.16
Current: 85.95
63.09
108.16
Days Sales Outstanding 67.31
DHR's Days Sales Outstanding is ranked higher than
52% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.84 vs. DHR: 67.31 )
Ranked among companies with meaningful Days Sales Outstanding only.
DHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.46  Med: 67.29 Max: 97.75
Current: 67.31
54.46
97.75
Days Payable 66.52
DHR's Days Payable is ranked higher than
55% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.91 vs. DHR: 66.52 )
Ranked among companies with meaningful Days Payable only.
DHR' s Days Payable Range Over the Past 10 Years
Min: 59.9  Med: 70.23 Max: 110.7
Current: 66.52
59.9
110.7

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.64
DHR's Dividend Yield % is ranked lower than
64% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.94 vs. DHR: 0.64 )
Ranked among companies with meaningful Dividend Yield % only.
DHR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.14  Med: 0.24 Max: 0.84
Current: 0.64
0.14
0.84
Dividend Payout Ratio 0.17
DHR's Dividend Payout Ratio is ranked higher than
85% of the 66 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.34 vs. DHR: 0.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DHR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.03  Med: 0.03 Max: 0.22
Current: 0.17
0.03
0.22
3-Year Dividend Growth Rate 78.60
DHR's 3-Year Dividend Growth Rate is ranked higher than
97% of the 34 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DHR: 78.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DHR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.2 Max: 78.6
Current: 78.6
0
78.6
Forward Dividend Yield % 0.67
DHR's Forward Dividend Yield % is ranked lower than
66% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. DHR: 0.67 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.01
DHR's 5-Year Yield-on-Cost % is ranked higher than
91% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.46 vs. DHR: 6.01 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DHR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.31  Med: 2.25 Max: 7.89
Current: 6.01
1.31
7.89
3-Year Average Share Buyback Ratio 0.30
DHR's 3-Year Average Share Buyback Ratio is ranked higher than
88% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. DHR: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.3  Med: -1.5 Max: 0.3
Current: 0.3
-7.3
0.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.21
DHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
81% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.25 vs. DHR: 1.21 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.17 Max: 4.64
Current: 1.21
0.52
4.64
Price-to-Median-PS-Value 1.80
DHR's Price-to-Median-PS-Value is ranked lower than
82% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.04 vs. DHR: 1.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.86 Max: 2.03
Current: 1.8
0.12
2.03
Earnings Yield (Greenblatt) % 3.75
DHR's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.04 vs. DHR: 3.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.8  Med: 8 Max: 12.6
Current: 3.75
2.8
12.6
Forward Rate of Return (Yacktman) % 2.33
DHR's Forward Rate of Return (Yacktman) % is ranked lower than
62% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.57 vs. DHR: 2.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.1  Med: 20 Max: 27.2
Current: 2.33
2.1
27.2

More Statistics

Revenue (TTM) (Mil) $17,432.20
EPS (TTM) $ 3.13
Beta1.03
Short Percentage of Float0.55%
52-Week Range $75.71 - 88.01
Shares Outstanding (Mil)694.69

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 17,969 18,716 19,377
EPS ($) 3.94 4.31 4.75
EPS without NRI ($) 3.94 4.31 4.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.22%
Dividends per Share ($) 0.62 0.64 0.78
» More Articles for DHR

Headlines

Articles On GuruFocus.com
Danaher Schedules Second Quarter 2017 Earnings Conference Call Jun 21 2017 
Danaher Announces Pricing Of Euro-Denominated Senior Notes Offering Jun 20 2017 
Danaher to Present at Goldman Sachs Global Healthcare Conference Jun 08 2017 
Danaher To Present At Bernstein Strategic Decisions Conference May 25 2017 
Danaher To Present At Bank Of America Merrill Lynch Health Care Conference May 10 2017 
Danaher Announces Quarterly Dividend May 09 2017 
Danaher Reports First Quarter 2017 Results Apr 20 2017 
Valeant: It's Not a Game of Chess - The Lessons Apr 16 2017 
A Socially Conscious Guru Apr 07 2017 
Chuck Akre Buys Moody's and Dollar General, Sells MasterCard Mar 29 2017 

More From Other Websites
Danaher Corp. :DHR-US: Earnings Analysis: Q2, 2017 By the Numbers : July 21, 2017 Jul 21 2017
Danaher tops Street 2Q forecasts Jul 20 2017
Edited Transcript of DHR earnings conference call or presentation 20-Jul-17 12:00pm GMT Jul 20 2017
So Two Breakup Candidates Walk Into Earnings Day... Jul 20 2017
Danaher (DHR) Q2 Earnings Top Estimates, Up Y/Y, View Raised Jul 20 2017
Danaher (DHR) Beats on Q2 Earnings & Revenues, Guides Up Jul 20 2017
Investor Network: Danaher Corporation to Host Earnings Call Jul 20 2017
Danaher Reports Second Quarter 2017 Results Jul 20 2017
Danaher (DHR) to Report Q2 Earnings: Will it Disappoint? Jul 18 2017
ETFs with exposure to Danaher Corp. : July 14, 2017 Jul 14 2017
Danaher Corp. breached its 50 day moving average in a Bullish Manner : DHR-US : July 14, 2017 Jul 14 2017
Wells Fargo Sets 'Market Perform' Rating on Danaher Jul 13 2017
There's More Than Meets the Eye to Danaher Corporation Jul 07 2017
Danaher Corp. breached its 50 day moving average in a Bearish Manner : DHR-US : June 30, 2017 Jun 30 2017
Danaher Schedules Second Quarter 2017 Earnings Conference Call Jun 21 2017
Danaher Announces Pricing Of Euro-Denominated Senior Notes Offering Jun 20 2017
ETFs with exposure to Danaher Corp. : June 15, 2017 Jun 15 2017
Danaher to Present at Goldman Sachs Global Healthcare Conference Jun 08 2017
Herbalife cuts sales outlook, Time Warner gets some 'Wonder Woman' power, Ebay upgraded Jun 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}